Theranica
高管
生物技术
Theranica 拥有 2,345 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Genus (联合王国)。
Popular M&A news in 生物技术
- Latigo Biotherapeutics 刚刚宣布为 150 筹款数百万美元。 (公布2025三月24号).
- AlloVir and Kalaris Therapeutics have announced they will merge (公布2025三月24号)..
- Purespring Therapeutics 刚刚宣布为 105 筹款数百万美元。 (公布2025三月14号).
生物技术 行业的其他推荐联系人
消息
Theranica 的最新新闻稿
- FDA Expands the Age Indication for Nerivio® as the First-and-Only REN Wearable for Migraine Treatment for Children Aged Eight and Above
- More States Join the Movement: The Nerivio® REN Wearable Now Covered by Arizona, New Jersey, Ohio, and Virginia Medicaid Programs
- New Study Evaluates Use of the Nerivio® REN Wearable for Treatment of Migraine in Children Under the Age of 12
- Colorado Medicaid's Decision to Cover the Nerivio® REN Wearable Expands Access for Nearly Two Million Americans to Drug-Free, Dual Use Migraine Treatment
- DC Medicaid Becomes the First Medicaid Plan to Cover the Nerivio® REN Wearable, a Non-Drug Treatment for Migraine
- Theranica's REN Wearable Becomes the First Ever Non-Pharmacological Migraine Treatment to Receive Commercial Coverage in the USA
- New Study Found Preventive Impact in Adolescents Who Frequently Used Nerivio® for Abortive Treatment of Migraine
- Theranica Enters Into Agreement With Dr. Reddy's for Commercializing Nerivio® in Europe
- New Study Demonstrates Consistent Positive Long-Term Adherence and Efficacy of Nerivio® for Treatment of Migraine
- First Migraine Neuroband Addressing Unmet Needs of Adolescents to Debut at 2023 Child Neurology Society Annual Meeting
- View more press releases Close
